Glenmark Pharmaceuticals receives ANDA approval for Lacosamide Tablets

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (USFDA) for its Lacosamide Tablets1 USP, 50 mg, 100 mg, 150 mg and 200 mg, the generic version of Vimpat®2 Tablets, 50 mg, 100 mg, 150 mg and 200 mg of UCB, Inc. The company plans to launch the product immediately.

Glenmark’s current portfolio consists of 174 products authorized for distribution in the U.S.
marketplace and 45 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings,
Glenmark continues to identify and explore external development partnerships to supplement and
accelerate the growth of its existing pipeline and portfolio.